drugset
Drugs / L-Tryptophan
last change Jul 2025 re-read 3 minutes ago

L-Tryptophan

also known as Tryptan

Other / unclassified

Developed for
delirium · celiac disease
Investigated by
University of Colorado, Denver

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Maapliv — 2025-07-28 europa.eu ↗

Trials 1

today
EU approved 2025
NCT00865202 · Ph 3
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT00865202 Dec 2008 → Dec 2012 delirium University of Colorado, Denver Completed No outcome recorded
Comparator or background therapy1 trial
— NCT05576038 Comparator Dec 2022 → Apr 2025 overdue celiac disease, inborn disorder of tryptophan metabolism McMaster University Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as L-tryptophan ClinicalTrials.gov intervention name — accepted as the source's own label NCT00865202 ↗
1

NCT05576038 ↗
Known as Tryptan “L-tryptophan* supplements (Tryptan, Valeant Canada LP): each treatment capsule contains 500 mg of L-Tryptophan” NCT05576038 ↗
Action Activate “responsible for activating the aryl hydrocarbon receptor (AhR)” NCT05576038 ↗
Modality Other / unclassified “L-tryptophan is an essential amino acid responsible for activating the aryl hydrocarbon receptor (AhR).” NCT05576038 ↗
Route Oral “Oral Tryptophan Supplementation” NCT05576038 ↗